PT125 - PURE-02: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (Pembro), preceding radical nephroureterectomy (RNU), for patients with localized high-risk urothelial carcinoma of the upper urinary tract (UTUC)

https://doi.org/10.1016/S1569-9056(19)31329-6Get rights and content

References (0)

Cited by (0)

View full text